Zevra Therapeutics, Inc. Share Price & Technical Analysis
ZVRA · $10.03 (-4.39%)
Healthcare / Biotechnology
$10.03
-4.39%
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Ph…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-2% return in May, 4% avg return in past 3 year May month.
12% return in 2026, 38% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | 6% | 9% | -2% | – | – | – | – | – | – | – | 12% |
| 25 | -7% | 4% | -7% | -4% | 18% | 2% | 28% | -18% | 6% | 9% | -18% | 7% | 19% |
| 24 | -11% | 16% | -15% | -12% | 2% | 4% | 33% | 18% | -10% | 17% | 13% | -12% | 45% |
| 23 | 20% | 7% | -4% | -2% | -7% | 0% | -4% | 4% | -6% | -6% | 7% | 40% | 49% |
| 22 | -18% | -18% | -15% | -12% | 5% | -2% | 24% | 0% | 13% | -11% | -14% | -4% | -53% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$642.58M
P/E ratio
5.41
52W high
$13.16
52W low
$7.16
Volume
13,64,549
Beta
0.88
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Zevra Therapeutics, Inc. share price today?
- Zevra Therapeutics, Inc. (ZVRA) last traded around $10.03 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ZVRA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ZVRA. Download the app for real-time alerts.
- How can I analyze Zevra Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.